SCHEDULE 13G/A: Key Investors Disclose Significant 9.99% Stake in PharmaCyte Biotech

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of approximately 9.99% of PharmaCyte Biotech, Inc.'s common stock as of December 31, 2024, through a Schedule 13G filing.

Summary

• The filing identifies Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC as the Reporting Persons.
• The issuer is PharmaCyte Biotech, Inc., with its common stock having a $0.0001 par value per share and CUSIP Number 717512X203.
• As of December 31, 2024, Intracoastal Capital LLC and Mitchell P. Kopin each beneficially owned 714,844 shares of Common Stock, representing approximately 9.99% of the class.
• This ownership for Intracoastal and Mr. Kopin includes 527,376 shares held directly by Intracoastal and 187,468 shares issuable upon exercise of Intracoastal Warrant 1.
• Daniel B. Asher beneficially owned 705,663 shares of Common Stock as of December 31, 2024, also representing approximately 9.99% of the class.
• Mr. Asher's beneficial ownership consists of 527,376 shares held by Intracoastal, 82,727 shares held directly by Mr. Asher, and 95,560 shares issuable upon exercise of Intracoastal Warrant 1.
• The beneficial ownership percentages are calculated based on 6,968,134 shares of Common Stock outstanding as of December 9, 2024, as reported by the Issuer, plus the shares issuable upon exercise of relevant warrants.
• All warrants (Intracoastal Warrant 1, 2, 3, and Asher Warrant) contain blocker provisions designed to prevent the holder's beneficial ownership from exceeding specific thresholds (9.99% or 4.99%).
• Without these blocker provisions, Intracoastal and Mr. Kopin would have been deemed to beneficially own 3,469,023 shares, and Mr. Asher would have been deemed to beneficially own 4,160,303 shares.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Stakeholder Impact

• Shareholders: Disclosure of significant ownership by key investors may influence market perception and trading activity.

Key Dates

Keywords

PharmaCyte Biotech, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, investor disclosure, stakeholder, equity, biotech